Workflow
Real estate revenue
icon
Search documents
Insights Into American Healthcare REIT (AHR) Q2: Wall Street Projections for Key Metrics
ZACKS· 2025-08-06 14:16
Core Insights - American Healthcare REIT (AHR) is expected to report quarterly earnings of $0.40 per share, reflecting a 21.2% increase year over year [1] - Analysts forecast revenues of $544.78 million, indicating an 8% year-over-year growth [1] - The consensus EPS estimate has remained unchanged over the past 30 days, suggesting analysts' reassessment of projections [1] Revenue Estimates - Analysts predict 'Revenues- Resident fees and services' to be $513.45 million, representing a 12.1% year-over-year increase [4] - 'Revenues- Real estate revenue' is estimated at $42.34 million, indicating a 9.1% decline from the previous year [4] Company Performance - Depreciation and amortization is expected to be $41.41 million according to analysts [4] - AHR shares have increased by 12.2% in the past month, outperforming the Zacks S&P 500 composite, which rose by 0.5% [4] - AHR holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the overall market in the near term [4]
Compared to Estimates, American Healthcare REIT (AHR) Q1 Earnings: A Look at Key Metrics
ZACKS· 2025-05-09 01:00
Core Insights - American Healthcare REIT (AHR) reported revenue of $540.6 million for Q1 2025, marking an 8.2% year-over-year increase and exceeding the Zacks Consensus Estimate of $538.59 million by 0.37% [1] - The company achieved an EPS of $0.38, a significant improvement from -$0.04 a year ago, and surpassed the consensus EPS estimate of $0.37 by 2.70% [1] Revenue Breakdown - Resident fees and services generated $497.18 million, slightly above the average estimate of $495.43 million from two analysts [4] - Real estate revenue was reported at $43.43 million, which fell short of the average estimate of $44.43 million from two analysts [4] Stock Performance - Over the past month, shares of American Healthcare REIT have returned +12.3%, outperforming the Zacks S&P 500 composite's +11.3% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]